These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38634685)

  • 21. Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis.
    Villanueva C; Albillos A; Genescà J; Garcia-Pagan JC; Brujats A; Calleja JL; Aracil C; Bañares R; Morillas RM; Poca M; Peñas B; Augustin S; Abraldes JG; Alvarado E; Torres F; Bosch J;
    J Hepatol; 2021 Sep; 75(3):589-599. PubMed ID: 33905794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carvedilol to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by liver stiffness: study protocol for a randomied, double-blind, placebo-controlled, multicentre trial in China.
    Liu C; Zhang L; Zhang S; Li X; Wong YJ; Liang X; Wang Y; Wu X; Gou W; Lv J; Hu S; Fu J; Huang J; Ge G; Huang M; Wang F; Zhang Q; Ren T; Meng Z; Ding D; Zhuoga B; Zhuoga C; Fan J; Dang D; Miao L; Song Z; Xiao X; Wu H; Jiang K; Liu T; Gao Y; Ma L; Fang T; Wang Y; Zhang Q; Zhu D; Ji D; Cao Z; Zeng QL; Li J; Chen P; Wei Y; Tong Z; Hong Z; Liang X; Li Y; Nan Y; Qi X
    BMJ Open; 2024 Jul; 14(7):e081623. PubMed ID: 38991669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Measurement of hepatic venous pressure gradient in liver cirrhosis: relationship with the status of cirrhosis, varices, and ascites in Korea].
    Kim MY; Baik SK; Suk KT; Yea CJ; Lee IY; Kim JW; Cha SH; Kim YJ; Um SH; Han KH
    Korean J Hepatol; 2008 Jun; 14(2):150-8. PubMed ID: 18617762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis.
    Villanueva C; Torres F; Sarin SK; Shah HA; Tripathi D; Brujats A; Rodrigues SG; Bhardwaj A; Azam Z; Hayes PC; Jindal A; Abid S; Alvarado E; Bosch J;
    J Hepatol; 2022 Oct; 77(4):1014-1025. PubMed ID: 35661713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation of HVPG level with ctp score, MELD Score, ascites, size of varices, and etiology in cirrhotic patients.
    Ramanathan S; Khandelwal N; Kalra N; Bhatia A; Dhiman RK; Duseja AK; Chawla YK
    Saudi J Gastroenterol; 2016; 22(2):109-15. PubMed ID: 26997216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites.
    Téllez L; Ibáñez-Samaniego L; Pérez Del Villar C; Yotti R; Martínez J; Carrión L; Rodríguez de Santiago E; Rivera M; González-Mansilla A; Pastor Ó; Bermejo J; Bañares R; Albillos A
    J Hepatol; 2020 Dec; 73(6):1404-1414. PubMed ID: 32446716
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beta-adrenergic blockade in cirrhosis - harmful or helpful?
    Møller S; Danielsen KV; Nabilou P; Kimer N; Bendtsen F
    Expert Rev Gastroenterol Hepatol; 2023; 17(6):519-529. PubMed ID: 37202907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension.
    Turco L; Reiberger T; Vitale G; La Mura V
    Liver Int; 2023 Jun; 43(6):1183-1194. PubMed ID: 36897563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increase in Free Hepatic Venous Pressure Response to Beta-Blockers Predicts Variceal Bleeding in Cirrhotic Patients.
    Guo H; Xiao J; Wang Y; Zhang M; Zhuge Y; Zhang F
    Biomed Res Int; 2021; 2021():5587566. PubMed ID: 33997022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early rebleeding increases mortality of variecal bleeders on secondary prophylaxis with β-blockers and ligation.
    Ardevol A; Alvarado-Tapias E; Garcia-Guix M; Brujats A; Gonzalez L; Hernández-Gea V; Aracil C; Pavel O; Cuyas B; Graupera I; Colomo A; Poca M; Torras X; Concepción M; Villanueva C
    Dig Liver Dis; 2020 Sep; 52(9):1017-1025. PubMed ID: 32653417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Evaluation and Prognosis.
    Hernández-Gea V; Berzigotti A
    Dig Dis; 2015; 33(4):515-23. PubMed ID: 26159268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacologic prevention of variceal bleeding and rebleeding.
    Baiges A; Hernández-Gea V; Bosch J
    Hepatol Int; 2018 Feb; 12(Suppl 1):68-80. PubMed ID: 29210030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.
    Ferlitsch M; Reiberger T; Hoke M; Salzl P; Schwengerer B; Ulbrich G; Payer BA; Trauner M; Peck-Radosavljevic M; Ferlitsch A
    Hepatology; 2012 Oct; 56(4):1439-47. PubMed ID: 22532296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Evaluation and treatment of portal hypertension].
    Brůha R; Petrtýl J
    Cas Lek Cesk; 2016; 155(2):22-6. PubMed ID: 27088788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis.
    Turco L; Garcia-Tsao G; Magnani I; Bianchini M; Costetti M; Caporali C; Colopi S; Simonini E; De Maria N; Banchelli F; Rossi R; Villa E; Schepis F
    J Hepatol; 2018 May; 68(5):949-958. PubMed ID: 29331339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of worsening portal hypertension during long-term medical treatment in patients with cirrhosis who had been classified as early good-responders on haemodynamic criteria.
    Merkel C; Bolognesi M; Berzigotti A; Amodio P; Cavasin L; Casarotto IM; Zoli M; Gatta A
    J Hepatol; 2010 Jan; 52(1):45-53. PubMed ID: 19914730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of a standardised protocol for hepatic venous pressure gradient measurement improves quality of readings and facilitates reduction of variceal bleeding in cirrhotics.
    Tey TT; Gogna A; Irani FG; Too CW; Lo HG; Tan BS; Tay KH; Lui HF; Chang PE
    Singapore Med J; 2016 Mar; 57(3):132-7. PubMed ID: 26996384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic markers in patients who have recovered from an acute variceal bleeding: role of HVPG measurement.
    Bañares R; Catalina MV; Ripoll C; Rincón D
    Dis Markers; 2011; 31(3):165-9. PubMed ID: 22045402
    [No Abstract]   [Full Text] [Related]  

  • 39. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.
    Frenette C; Kayali Z; Mena E; Mantry PS; Lucas KJ; Neff G; Rodriguez M; Thuluvath PJ; Weinberg E; Bhandari BR; Robinson J; Wedick N; Chan JL; Hagerty DT; Kowdley KV;
    J Hepatol; 2021 Feb; 74(2):274-282. PubMed ID: 33038432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis.
    Villanueva C; Graupera I; Aracil C; Alvarado E; Miñana J; Puente Á; Hernandez-Gea V; Ardevol A; Pavel O; Colomo A; Concepción M; Poca M; Torras X; Reñe JM; Guarner C
    Hepatology; 2017 May; 65(5):1693-1707. PubMed ID: 28100019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.